External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands
PDxBR demonstrated robust prognostic performance in an independent cohort, supporting its potential as a scalable, reproducible alternative to genomic assays for individualized risk stratification in early-stage breast cancer.
Authors
- Alexander Shtabsky (ORCID: https://orcid.org/0000-0003-1886-4950)
- Michael Donovan (ORCID: https://orcid.org/0000-0003-0772-598X)
- Brandon Veremis (ORCID: https://orcid.org/0000-0002-3934-9782)
- Aaron Feliz
- Pieter J. Westenend (ORCID: https://orcid.org/0000-0002-5509-920X)
- Claudia J. C. Meurs (ORCID: https://orcid.org/0000-0002-8643-3717)
- Xiaozhu Zhang (ORCID: https://orcid.org/0000-0002-7064-3023)
- Marcel Prastawa (ORCID: https://orcid.org/0000-0002-0278-9637)
- Abishek Sainath Madduri
- Rebecca DeAngel
- Gerardo Fernández (ORCID: https://orcid.org/0000-0002-6081-6437)
- Juan Carlos Cruz (ORCID: https://orcid.org/0000-0001-6364-4776)
Institutions
- Mount Sinai Health System (US)
- Capital District Center for Independence (US)
- Precision for Medicine (United States) (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1186/s13058-025-02104-8
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00